Press Releases

BioIVT Unveils COVID-19 Panel to Accelerate Vaccine-generated Immune Response Research

The panel contains serum or peripheral blood mononuclear cells (PBMCs) isolated from pre- and post-vaccination blood samples.

THREAD and 1nHealth Partner to Optimize Participant Recruitment in Decentralized Clinical Trials

Strategic alliance will streamline patient-centric recruitment for sponsors and CROs, ultimately improving recruitment and retention outcomes in decentralized clinical trials

Aalto Bio Reagents is pleased to announce the availability of the first highly reactive recombinant Rubella Spike Ectodomain (E1-E2) antigen

Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult

Albumedix Ltd., the world leader in recombinant human albumin, has entered into a collaboration agreement with Cell and Gene Therapy Catapult (CGT Catapult), an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, to investigate the use of Albumedix´ proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.

Calyx Supports Breakthrough Therapy Approvals for Oncology Treatments

Calyx Medical Imaging and other eClinical services provide critical support for clinical development programs to deliver much-needed therapies to market

Alfa Chemistry Recently Launched a Sub-website for Functional Polymers

Syntekabio and Hanmi Science Join Forces to Co-Develop New Promising COVID-19 Treatments Using Drug Repurposing Technologies

Syntekabio has announced a strategic collaboration with Hanmi Science to co-develop breakthrough COVID-19 treatments using drug repositioning technologies.

Prime Global and Raremark form strategic partnership to transform solutions and outcomes for patients with rare diseases

Medical communications company, Prime Global, and healthcare technology company, Raremark®, announced today that they have formed a strategic partnership to transform solutions for patients with rare diseases. Together, the companies will uncover insights into the entire patient journey that will allow the creation of truly patient-centric drug development and commercialisation programs. Focusing on the needs of patients is the key to powerful communications that make a tangible difference to patient outcomes.

CluePoints’ Risk-Based Quality Management Platform Instrumental in Data Quality Oversight of COVID-19 Trials

CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software for clinical trials, today announced that its Risk-Based Quality Management (RBQM) platform has been critical in supporting numerous Pharmaceutical companies and CROs to interrogate data in their global COVID-19 vaccine and antiviral antibody trials to ensure data quality and integrity.

Alfa Chemistry Launches MOF Chemicals for the Science Community

MedAI Launches Artificial Intelligence Drug Discovery (AIDD) Platform to Accelerate Drug Development

To accelerate drug development, MedAI, an expert of AI-assisted R&D research company, announces that it has completed the construction of its Artificial Intelligence Drug Discovery (AIDD) Platform. With this platform, scientists at MedAI are now capable of providing innovative solutions for pharmaceutical companies to push forward their drug discovery projects.

Alfa Chemistry Provides Wide Choices of Pyridinium Ionic Liquids for Scientific Research

Pyridinium ionic liquids are widely applied in Diels-Alder reaction, Friedel-Crafts reaction, Suzuki reaction, Grignard Reaction as well as the synthesis of some pharmaceutical agents. To meet the growing needs for this type of chemicals, Alfa Chemistry recently announced to provide wide choices of pyridinium ionic liquids for clients both at home and abroad. Most of them are in stock and can be delivered to buyers within a few business days.

eNUVIO is Launching the OMEGA-96 Device

Today, eNUVIO has announced the launch of their latest innovative microfluidic device for neuronal compartmentalization and co-culture experiments — the OMEGA-96. This first of its kind microplate will help to improve the success and efficiency of drug discovery and safety toxicology in neurological research areas, particularly in the field of neurodegenerative and neuromuscular diseases.

Parent Project Muscular Dystrophy’s Duchenne Registry Participant Response Rate Increases Exponentially in 2020 Utilizing THREAD

Year one of The Duchenne Registry powered by THREAD’s decentralized platform sees uptick in survey completion, data collection, and community engagement

Shimmer’s Verisense® Wearable Sensing Platform Selected for Boston University Brain Health Studies

These studies, which are funded by the American Heart Association, will use wearable sensors to increase knowledge of the links between brain and heart health.

‘UK government can deliver Brexit benefit with world’s best medicines security’ say FarmaTrust

Company forewarns the UK is risking fake COVID-19 vaccines and other medicines without a new system

RheinCell Therapeutics Achieves Milestone GMP Certification to Manufacture Cord Blood-Derived iPSCs for Safe and Compliant Cell Therapies

RheinCell Therapeutics GmbH, a developer and manufacturer of human induced pluripotent stem cells (iPSCs) as starting materials for cell therapies, has announced it has received Good Manufacturing Practice (GMP) certification and Manufacturing Authorization. The GMP certification paves the way for the company to deliver fully characterized clinical-grade iPSCs that are derived from human cord blood cells for the development of cell-based therapies. This marks a landmark achievement for RheinCell, which is now among a select few iPSCs manufacturers to have received the critical certification.

Gut Microbiota Bioinformatics Services Now Available by the GutFlora Omics Platform

GutFlora Omics platform belongs to Creative Proteomics. It has more than 10 years of experience in providing advanced multi-omics services, and provides services and support to customers through comprehensive intestinal flora research solutions. The product manager has recently announced the fully-developed gut microbiota bioinformatics services, which help understand how the gut microbiota colonizes, varies and interacts with the host, and even how to associate with diseases can be of great value in the treatment of these diseases, such as inflammatory bowel disease (IBD), diabetes, mental disorders, and cancers.

Global healthtech company Raremark appoints Nicki Grundy as its Chief Financial Officer

Raremark, the global healthtech company specialising in rare disease, has appointed Nicki Grundy as Chief Financial Officer to support the accelerated levels of growth the company is experiencing.

Alfa Chemistry: Instrumental Analytical Reagents Are Now Accessible

Alfa Chemistry announced in a statement that the company starts to provide varieties of instrumental analytical reagents for consumers worldwide. In addition to other reagents that are previously released, now the company’s supply range of products are widely broadened, which encompasses: chromatography standards and derivatization reagents, Ion Sensor Materials, Laboratory Supplies, LPLC/TLC/Paper Chromatography, and Titration.